Sonoscape Medical Corp. Class A

Sonoscape Medical Corp. Class A

SSZSE:300633
21.04
CNY
-0.33
(-1.54%)
0.41EPS
47.42P/E
8.25BMarket Cap
Apr 09Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.48
1.8
1.88
1.99
2.55
3.06
3.09
3.02
3.62
4.1
4.95
4.67
5.38
5.7
Basic EPS, GAAP
0.18
0.37
0.29
0.36
0.49
0.63
0.25
-0.12
0.62
0.86
1.06
0.33
0.46
0.41
Free Cash Flow per Basic Share
0.1
0.27
0.11
0.34
0.24
0.38
0.08
0.3
0.38
0.66
0.73
0.23
-0.44
- -
Dividend per Share
0.08
0.18
0.01
0.01
0.04
0.05
0.11
0.08
0.01
0.13
0.19
0.33
0.11
0.19
Book Value per Share
6.95
1.24
1.57
2
2.65
3.28
3.46
3.33
5.86
6.4
7.31
7.18
7.54
7.09
Tangible Book Value per Share
3.84
0.82
1.14
1.56
2.28
2.04
2.29
2.43
5.05
5.63
6.54
6.56
6.95
6.53
Basic Weighted Avg Shares
400
356
365
362
388
401
406
386
399
430
429
432
429
428
Sales/Revenue/Turnover
592
640
686
719
989
1,227
1,254
1,163
1,445
1,763
2,120
2,014
2,309
2,438
Operating Margin (%)
25.05
20.52
11.88
12.25
22.57
22.5
11.05
17.34
22.09
23.15
23.98
9.84
7.99
10.21
Depreciation Expense
10
12
14
16
15
19
25
29
54
53
66
86
103
- -
Net Income, GAAP
71
132
106
130
190
253
102
-46
247
370
454
142
197
175
Effective Tax Rate (%)
19.69
9.58
10.59
7.19
8.49
6.9
5.72
- -
2.74
3.18
4.09
- -
- -
- -
Profit Margin (%)
11.93
20.6
15.44
18.13
19.21
20.59
8.1
-3.98
17.12
20.98
21.43
7.07
8.54
7.19
Working Capital
285
371
489
551
869
677
850
652
1,576
1,765
2,057
1,892
1,796
1,526
LT Debt
25
73
58
- -
- -
18
256
67
69
27
34
76
65
214
Total Equity
365
445
566
720
1,059
1,311
1,404
1,345
2,355
2,740
3,146
3,108
3,262
3,014
Return on Invested Capital (%)
10.34
19.79
9.81
9.89
20.6
19.86
6.06
- -
9.96
13.93
15.05
- -
- -
- -
Return on Capital (%)
17.15
25.75
15.99
17.78
20.55
19.76
6.94
- -
11.77
13.77
14.87
- -
- -
- -
Return on Common Equity (%)
20.74
33.27
20.94
20.28
21.36
21.32
7.48
-3.37
13.36
14.52
15.44
4.55
6.19
5.72

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
213
101
149
LT Borrowings
41
180
177
LT Finance Leases
22
20
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
433
425
425
Market Capitalization
11,060
7,813
8,250

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,703
2,427
2,375
Cash, Cash Equivalents & STI
1,420
1,087
1,001
Accounts Receivable, Net
290
266
277
Inventories
900
963
954
Total Current Liabilities
914
814
849
Payables & Accruals
- -
- -
- -
ST Debt
213
101
149
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.1%
22%
4.96%
Free Cash Flow
20.4%
-46.12%
-290.78%
Net Income, GAAP
-69.57%
-118.42%
38.54%
Sales/Revenue/Turnover
13.75%
15.23%
14.65%
Total Cash Common Dividend
128.39%
182.15%
-67.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
479
533
386
616
2,014
2025
430
534
- -
850
2,309
2026
481
573
535
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.16
-0.14
0.08
0.33
2025
0.02
0.09
- -
0.38
0.46
2026
-0.03
0.06
-0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.32
- -
- -
0.33
2025
- -
0.1
- -
- -
0.11
2026
- -
0.18
- -
- -
- -

Company Description

CEO
Kun Xiang Wu
Full Time Employees
3,133
Sector
Health technology
Industry
Medical specialties
Address
Kaili Medical Building Shenzhen GD China 518107
IPO Date
Apr 6, 2017
Business
SonoScape Medical Corp. (300633.SZ) develops, manufactures and sells medical diagnostic and treatment equipment with a focus on ultrasound imaging, endoscopy, minimally invasive surgery and cardiovascular intervention products. The company offers trolley and portable color Doppler ultrasound systems, black-and-white ultrasound systems, veterinary ultrasound equipment including the ProPet series, transducers; high-definition endoscopy systems such as the HD-500, HD-550, HD-580 and iEndo platforms with gastroscopes, colonoscopes, bronchoscopes, duodenoscopes, endoscopic ultrasound scopes; minimally invasive surgical products including laparoscopes, thoracoscopes, hysteroscopes, arthroscopes; cardiovascular interventional products such as the V20 Series intravascular ultrasound platform; and related image processors, light sources, camera systems and peripheral equipment for applications in radiology, OB/GYN, MSK, vascular, urology, pulmonology, gastroenterology and veterinary care. Founded in 2002 and headquartered in Shenzhen, China, SonoScape operates branch offices in 30 major cities across China and maintains global R&D centers in Shenzhen, Shanghai, Wuhan, Tuttlingen, Tokyo, San Francisco and Seattle, serving customers in over 170 countries and regions. Recent developments include the launch of the P80 Elite series for women's care, ProPet 80/70/60 veterinary ultrasound systems, S-Fetus 4.0 obstetric software, SV-M4K220 4K 3D fluorescence endoscopy platform, multiple products gaining EU-MDR CE-Mark certification, recognition as a National Enterprise Technology Center, CNAS laboratory accreditation and collaboration with OrbusNeich on intravascular ultrasound distribution.